Antibody therapies could be a bridge to a coronavirus vaccine - but will the world benefit?

Nature. 2020 Aug;584(7821):333-334. doi: 10.1038/d41586-020-02360-y.
No abstract available

Keywords: Infection; Medical research; Policy; SARS-CoV-2.

Publication types

  • News

MeSH terms

  • Antibodies, Monoclonal / biosynthesis
  • Antibodies, Monoclonal / economics*
  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Neutralizing / biosynthesis
  • Antibodies, Neutralizing / economics*
  • Antibodies, Neutralizing / immunology
  • Antibodies, Neutralizing / therapeutic use*
  • Bioreactors
  • COVID-19
  • COVID-19 Vaccines
  • Coronavirus Infections / drug therapy*
  • Coronavirus Infections / immunology
  • Coronavirus Infections / prevention & control*
  • Coronavirus Infections / therapy
  • Coronavirus Infections / virology
  • Humans
  • Immunization, Passive
  • Pandemics / prevention & control*
  • Pneumonia, Viral / drug therapy*
  • Pneumonia, Viral / immunology
  • Pneumonia, Viral / prevention & control*
  • Pneumonia, Viral / virology
  • Randomized Controlled Trials as Topic
  • Time Factors
  • Viral Vaccines / immunology
  • Viral Vaccines / supply & distribution

Substances

  • Antibodies, Monoclonal
  • Antibodies, Neutralizing
  • COVID-19 Vaccines
  • Viral Vaccines

Supplementary concepts

  • COVID-19 serotherapy